A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
This research study is investigating a new medication called Sonrotoclax for adults living with Waldenström Macroglobulinemia (WM), a type of blood cancer. The study will look at how safe and effective Sonrotoclax is when given on its own to patients whose previous treatments haven't worked well or whose cancer has returned. It will also be tested in combination with another drug, Zanubrutinib, for those who haven't received any treatment for their WM yet. The main goals are to see if the treatment can reduce the signs and symptoms of WM, or even make the cancer disappear, and to understand any side effects people might experience. Sonrotoclax works by targeting a protein called BCL2, which is often found in high levels in people with WM.
A colpo d'occhio
Di cosa tratta questo studio?
This study is a research project designed to help us understand more about a new treatment for Waldenström Macroglobulinemia (WM). WM is a rare type of cancer that affects certain white blood cells. The new drug being studied is called Sonrotoclax. Researchers want to see if Sonrotoclax can help improve the health of people with WM.
The study will explore two main areas. Firstly, it will look at Sonrotoclax by itself in people who have already had treatment for their WM, but it hasn't worked as hoped, or their cancer has come back. Secondly, it will combine Sonrotoclax with another existing drug, Zanubrutinib, for people who are newly diagnosed with WM and haven't started any treatment yet. The main things the study will measure are whether the cancer shrinks or disappears, and what kind of side effects, if any, people experience.
Sonrotoclax works by targeting a specific protein called BCL2, which plays a role in how cancer cells survive. In many cancers, including WM, this protein can be overactive. By blocking BCL2, scientists hope to stop the cancer cells from growing and encourage them to die. This worldwide study plans to involve about 105 adult participants and will last for approximately five years. You might see the study sponsored by BeiGene or BeOne Medicines, as the company recently changed its name.
Punti chiave
- This study evaluates a new drug, Sonrotoclax, for Waldenström Macroglobulinemia (WM).
- It's being tested alone for previously treated WM and with Zanubrutinib for untreated WM.
- Sonrotoclax targets a protein involved in cancer cell survival.
- The study aims to understand the treatment's safety and effectiveness.
- Participation involves taking daily pills and regular check-ups over several years.
- It's a 'Phase 2' study, meaning it's exploring safety and early signs of effectiveness.
Chi può essere idoneo?
To be considered for this study, you would need to have a confirmed diagnosis of Waldenström Macroglobulinemia (WM). Your medical team would also need to confirm that your WM meets certain guidelines for requiring treatment.
For some parts of the study, you would need to have WM that has either come back after treatment, or hasn't responded well to previous treatments. For another part of the study, it's important that you haven't received any prior treatment for your WM, apart from a procedure called plasmapheresis if you needed it.
There are also some things that would prevent you from taking part. For example, if your WM has spread to your brain or spinal cord, or if your WM has changed into a more aggressive form of lymphoma. You also wouldn't be able to participate if you've had another type of cancer within the last two years, or have an uncontrolled infection.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- I have a confirmed diagnosis of Waldenström Macroglobulinemia (WM).
- My WM requires treatment according to my doctor.
- I am an adult aged 18 or older.
- My WM is either relapsed/refractory OR I have not received previous treatment for WM.
- My WM has not spread to my brain or spinal cord.
- I do not have an uncontrolled infection at the moment.
Cosa comporta la partecipazione?
If you decide to take part in this study, you will receive the study medication, Sonrotoclax, as a pill that you take by mouth. The overall study will involve regular visits and assessments with the study team to monitor your health, how you're responding to the treatment, and any side effects you might experience. These assessments typically include blood tests, physical examinations, and possibly scans or other tests to check on your WM. The total time commitment for individual participants in the study could be up to approximately five years, including treatment and follow-up.
Rischi e benefici potenziali
Locations (72)
- City of Hope National Medical CenterCodice postale verificatoDuarte, Stati Uniti
- Colorado Blood Cancer InstituteCodice postale verificatoDenver, Stati Uniti
- Medstar Georgetown University HospitalCodice postale verificatoWashington D.C., Stati Uniti
- University of MiamiCodice postale verificatoMiami, Stati Uniti
- Northwestern Medicine Cancer CenterCodice postale verificatoWarrenville, United States
- Mission Cancer and BloodCodice postale verificatoWaukee, United States
- University of Maryland Greenebaum Comprehensive Cancer CenterCodice postale verificatoBaltimora, Stati Uniti
- Dana Farber Cancer InstituteCodice postale verificatoBoston, Stati Uniti
- Mayo Clinic RochesterCodice postale verificatoRochester, Stati Uniti
- Hattiesburg Hematology and Oncology ClinicCodice postale verificatoHattiesburg, Stati Uniti
- Memorial Sloan Kettering Cancer Center MskccCodice postale verificatoNew York, Stati Uniti
- Atrium Health Levine Cancer Institute (Lci)Codice postale verificatoCharlotte, Stati Uniti
Domande comuni
What is Waldenström Macroglobulinemia?
It's a rare type of slow-growing blood cancer that affects certain white blood cells called lymphocytes, leading to too many abnormal cells in the bone marrow.
What does 'Relapsed/Refractory' mean?
Relapsed means your cancer came back after treatment. Refractory means your cancer didn't respond well to treatment, or it got worse while you were on treatment.
How does Sonrotoclax work?
Sonrotoclax targets a protein called BCL2, which helps cancer cells survive. By blocking this protein, the drug aims to stop cancer cell growth and encourage them to die.
Is Sonrotoclax available to everyone?
No, Sonrotoclax is an investigational drug, meaning it's still being studied in clinical trials and is not yet approved or available for general use.
Cosa succede dopo la fine dello studio?
After the study, the researchers will analyse all the information gathered. If the treatment is found to be safe and effective, it may eventually become a standard treatment option for WM, usually after further studies and approval from health authorities.
Come saperne di più
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.